<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02047981</url>
  </required_header>
  <id_info>
    <org_study_id>OPP1032340-A</org_study_id>
    <nct_id>NCT02047981</nct_id>
  </id_info>
  <brief_title>Mortality Reduction After Oral Azithromycin: Mortality Study</brief_title>
  <acronym>MORDORIMort</acronym>
  <official_title>Evaluating Impact of Azithromycin Mass Drug Administrations on All-cause Mortality and Antibiotic Resistance: Mortality Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our long-term goal is to more precisely define the role of mass azithromycin treatments as an
      intervention for reducing childhood mortality. We propose a single multi-site
      (multi-country), cluster-randomized trial comparing communities randomized to oral
      azithromycin with those randomized to placebo. We hypothesize that mass azithromycin
      treatments will reduce childhood mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will assess childhood mortality over three years, comparing communities where children
      aged 1-60 months receive biannual oral azithromycin (&quot;Azithromycin&quot; arm) for two years, to
      communities where the children receive biannual oral placebo (&quot;Control&quot; arm) for two years.
      During the third year at the Niger site only, everyone will receive azithromycin.

      This is a cluster-randomized trial; at each site, communities within a contiguous area of
      300,000 to 600,000 individuals will be randomized to azithromycin or placebo using simple
      random sampling.

      Niger contingency study: In the event that mass distributions of oral azithromycin are proven
      to reduce mortality in 1-60 month-old children, then we will treat all communities in Niger
      with mass azithromycin distributions to test whether the intervention continues to reduce
      childhood mortality after the initial 2 years of mass treatments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause Mortality Rate in Children Aged 1-60 Months</measure>
    <time_frame>24 Months</time_frame>
    <description>This is a single multi-site trial, with each country as a secondary analysis. Also, an interim analysis of efficacy and futility will be conducted according to a pre-specified plan in the Statistical Analysis Plan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause Mortality Rate in Children Aged 1-60 Months</measure>
    <time_frame>36 months</time_frame>
    <description>This was a pre-specified contingency study in Niger only in which all communities were treated with mass azithromycin during the third year of the study following the primary 24-month endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cause-specific Mortality Rate in Children Aged 1-60 Months, as Assessed From Verbal Autopsy (Niger Only)</measure>
    <time_frame>24 Months</time_frame>
    <description>Deaths were assessed via biannual population census. A pre-specified outcome was cause of death, assessed by verbal autopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness of Mass Azithromycin Administration, Per Averted Childhood Death</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause and Cause-specific Health Clinic Visits in 1-60 Month-old Children</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause-specific Mortality Rate in Children Aged 1-60 Months, as Assessed From Verbal Autopsy (Tanzania Only)</measure>
    <time_frame>24 Months</time_frame>
    <description>At 6-monthly intervals a census of the communities was conducted, and for child deaths a verbal autopsy was performed to ascertain the cause using a standardized diagnostic classification. Mortality due to pneumonia or diarrhea by age group and arm are shown in the outcome measure data table below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause-specific Mortality Rate in Children Aged 1-60 Months, as Assessed From Verbal Autopsy (Malawi Only)</measure>
    <time_frame>24 Months</time_frame>
    <description>Cause-specific mortality by intention-to-treat for the four main inferred causes of death in the study area.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">190238</enrollment>
  <condition>Childhood Mortality</condition>
  <arm_group>
    <arm_group_label>Biannual mass oral azithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years.
In Niger during year 3, all communities will be offered azithroymcin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biannual mass oral placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years
In Niger during year 3, all communities will be offered azithroymcin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.</description>
    <arm_group_label>Biannual mass oral azithromycin</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.</description>
    <arm_group_label>Biannual mass oral placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Communities

          -  The community location in target district.

          -  The community leader consents to participation in the trial

          -  The community's estimated population is between 200-2,000 people.

          -  The community is not in an urban area.

        Individuals - All children aged 1-60 months (up to but not including the 5th birthday), as
        assessed via biannual census.

        Exclusion Criteria:

        Individuals

        - Refusal of village chief (for village inclusion), or refusal of parent or guardian (for
        individual inclusion)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>60 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom M Lietman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine A Cook, MPH</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Proctor Foundation</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>College of Medicine at the University of Malawi, Blantyre</name>
      <address>
        <city>Blantyre</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Carter Center, Niger</name>
      <address>
        <city>Niamey</city>
        <country>Niger</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kongwa Trachoma Project</name>
      <address>
        <city>Kongwa</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London School of Hygiene &amp; Tropical Medicine</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malawi</country>
    <country>Niger</country>
    <country>Tanzania</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 24, 2014</study_first_submitted>
  <study_first_submitted_qc>January 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2014</study_first_posted>
  <results_first_submitted>August 29, 2019</results_first_submitted>
  <results_first_submitted_qc>January 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 3, 2020</results_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Childhood mortality</keyword>
  <keyword>Azithromycin</keyword>
  <keyword>Mass treatment</keyword>
  <keyword>Infection</keyword>
  <keyword>Verbal Autopsy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT02047981/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT02047981/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Biannual Mass Oral Azithromycin</title>
          <description>Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years.
In Niger during year 3, all communities will be offered azithroymcin.
Azithromycin: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.</description>
        </group>
        <group group_id="P2">
          <title>Biannual Mass Oral Placebo</title>
          <description>Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years
In Niger during year 3, all communities will be offered azithroymcin.
Placebo: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>MORDOR Stage I Year 1-2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="97047"/>
                <participants group_id="P2" count="93191"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87650"/>
                <participants group_id="P2" count="84474"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9397"/>
                <participants group_id="P2" count="8717"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>MORDOR Stage II Year 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37497"/>
                <participants group_id="P2" count="33294"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34611"/>
                <participants group_id="P2" count="30931"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2886"/>
                <participants group_id="P2" count="2363"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Biannual Mass Oral Azithromycin</title>
          <description>Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years.
In Niger during year 3, all communities will be offered azithroymcin.
Azithromycin: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.</description>
        </group>
        <group group_id="B2">
          <title>Biannual Mass Oral Placebo</title>
          <description>Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years
In Niger during year 3, all communities will be offered azithroymcin.
Placebo: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="97047"/>
            <count group_id="B2" value="93191"/>
            <count group_id="B3" value="190238"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age group</title>
              <category_list>
                <category>
                  <title>1-5 months</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7135"/>
                    <measurement group_id="B2" value="6870"/>
                    <measurement group_id="B3" value="14005"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6-11 months</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12777"/>
                    <measurement group_id="B2" value="12318"/>
                    <measurement group_id="B3" value="25095"/>
                  </measurement_list>
                </category>
                <category>
                  <title>12-23 months</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18557"/>
                    <measurement group_id="B2" value="17886"/>
                    <measurement group_id="B3" value="36443"/>
                  </measurement_list>
                </category>
                <category>
                  <title>24-59 months</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58578"/>
                    <measurement group_id="B2" value="56117"/>
                    <measurement group_id="B3" value="114695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47901"/>
                    <measurement group_id="B2" value="46019"/>
                    <measurement group_id="B3" value="93920"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49146"/>
                    <measurement group_id="B2" value="47172"/>
                    <measurement group_id="B3" value="96318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97047"/>
                    <measurement group_id="B2" value="93191"/>
                    <measurement group_id="B3" value="190238"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Niger</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40345"/>
                    <measurement group_id="B2" value="35747"/>
                    <measurement group_id="B3" value="76092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malawi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39386"/>
                    <measurement group_id="B2" value="39534"/>
                    <measurement group_id="B3" value="78920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tanzania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17316"/>
                    <measurement group_id="B2" value="17910"/>
                    <measurement group_id="B3" value="35226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of communities</title>
          <units>communities</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="762"/>
                    <measurement group_id="B2" value="750"/>
                    <measurement group_id="B3" value="1512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>All-cause Mortality Rate in Children Aged 1-60 Months</title>
        <description>This is a single multi-site trial, with each country as a secondary analysis. Also, an interim analysis of efficacy and futility will be conducted according to a pre-specified plan in the Statistical Analysis Plan.</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Biannual Mass Oral Azithromycin</title>
            <description>Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years.
In Niger during year 3, all communities will be offered azithroymcin.
Azithromycin: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.</description>
          </group>
          <group group_id="O2">
            <title>Biannual Mass Oral Placebo</title>
            <description>Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years
In Niger during year 3, all communities will be offered azithroymcin.
Placebo: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Mortality Rate in Children Aged 1-60 Months</title>
          <description>This is a single multi-site trial, with each country as a secondary analysis. Also, an interim analysis of efficacy and futility will be conducted according to a pre-specified plan in the Statistical Analysis Plan.</description>
          <units>deaths per 1000 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97047"/>
                <count group_id="O2" value="93191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6"/>
                    <measurement group_id="O2" value="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>All-cause Mortality Rate in Children Aged 1-60 Months</title>
        <description>This was a pre-specified contingency study in Niger only in which all communities were treated with mass azithromycin during the third year of the study following the primary 24-month endpoint.</description>
        <time_frame>36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Biannual Mass Oral Azithromycin</title>
            <description>Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years.
In Niger during year 3, all communities will be offered azithroymcin.
Azithromycin: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.</description>
          </group>
          <group group_id="O2">
            <title>Biannual Mass Oral Placebo</title>
            <description>Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years
In Niger during year 3, all communities will be offered azithroymcin.
Placebo: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Mortality Rate in Children Aged 1-60 Months</title>
          <description>This was a pre-specified contingency study in Niger only in which all communities were treated with mass azithromycin during the third year of the study following the primary 24-month endpoint.</description>
          <units>deaths per 1000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37497"/>
                <count group_id="O2" value="33294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" lower_limit="21.4" upper_limit="25.5"/>
                    <measurement group_id="O2" value="24.0" lower_limit="22.1" upper_limit="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cause-specific Mortality Rate in Children Aged 1-60 Months, as Assessed From Verbal Autopsy (Niger Only)</title>
        <description>Deaths were assessed via biannual population census. A pre-specified outcome was cause of death, assessed by verbal autopsy.</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Biannual Mass Oral Azithromycin</title>
            <description>Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years.
In Niger during year 3, all communities will be offered azithroymcin.
Azithromycin: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.</description>
          </group>
          <group group_id="O2">
            <title>Biannual Mass Oral Placebo</title>
            <description>Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years
In Niger during year 3, all communities will be offered azithroymcin.
Placebo: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.</description>
          </group>
        </group_list>
        <measure>
          <title>Cause-specific Mortality Rate in Children Aged 1-60 Months, as Assessed From Verbal Autopsy (Niger Only)</title>
          <description>Deaths were assessed via biannual population census. A pre-specified outcome was cause of death, assessed by verbal autopsy.</description>
          <units>Deaths per 1000 person years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40345"/>
                <count group_id="O2" value="35747"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injury</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" lower_limit="0.14" upper_limit="0.36"/>
                    <measurement group_id="O2" value="0.23" lower_limit="0.14" upper_limit="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malnutrition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" lower_limit="0.26" upper_limit="0.59"/>
                    <measurement group_id="O2" value="0.42" lower_limit="0.28" upper_limit="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AIDS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" lower_limit="0.06" upper_limit="0.23"/>
                    <measurement group_id="O2" value="0.12" lower_limit="0.06" upper_limit="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" lower_limit="0.19" upper_limit="0.46"/>
                    <measurement group_id="O2" value="0.28" lower_limit="0.17" upper_limit="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" lower_limit="0.63" upper_limit="1.09"/>
                    <measurement group_id="O2" value="1.22" lower_limit="0.96" upper_limit="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysentery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" lower_limit="0.55" upper_limit="0.98"/>
                    <measurement group_id="O2" value="1.14" lower_limit="0.88" upper_limit="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.01" lower_limit="2.59" upper_limit="3.49"/>
                    <measurement group_id="O2" value="3.60" lower_limit="3.11" upper_limit="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.01" upper_limit="0.12"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.01" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27" lower_limit="2.85" upper_limit="3.75"/>
                    <measurement group_id="O2" value="3.96" lower_limit="3.46" upper_limit="4.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.60" lower_limit="4.97" upper_limit="6.32"/>
                    <measurement group_id="O2" value="7.22" lower_limit="6.43" upper_limit="8.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemorrhagic fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" lower_limit="0.03" upper_limit="0.17"/>
                    <measurement group_id="O2" value="0.06" lower_limit="0.02" upper_limit="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.24" lower_limit="3.70" upper_limit="4.85"/>
                    <measurement group_id="O2" value="5.06" lower_limit="4.44" upper_limit="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unspecified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" lower_limit="1.17" upper_limit="1.75"/>
                    <measurement group_id="O2" value="1.81" lower_limit="1.49" upper_limit="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" lower_limit="20.9" upper_limit="23.9"/>
                    <measurement group_id="O2" value="27.3" lower_limit="25.5" upper_limit="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cost-effectiveness of Mass Azithromycin Administration, Per Averted Childhood Death</title>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause and Cause-specific Health Clinic Visits in 1-60 Month-old Children</title>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cause-specific Mortality Rate in Children Aged 1-60 Months, as Assessed From Verbal Autopsy (Tanzania Only)</title>
        <description>At 6-monthly intervals a census of the communities was conducted, and for child deaths a verbal autopsy was performed to ascertain the cause using a standardized diagnostic classification. Mortality due to pneumonia or diarrhea by age group and arm are shown in the outcome measure data table below.</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Biannual Mass Oral Azithromycin</title>
            <description>Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years.
In Niger during year 3, all communities will be offered azithroymcin.
Azithromycin: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.</description>
          </group>
          <group group_id="O2">
            <title>Biannual Mass Oral Placebo</title>
            <description>Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years
In Niger during year 3, all communities will be offered azithroymcin.
Placebo: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.</description>
          </group>
        </group_list>
        <measure>
          <title>Cause-specific Mortality Rate in Children Aged 1-60 Months, as Assessed From Verbal Autopsy (Tanzania Only)</title>
          <description>At 6-monthly intervals a census of the communities was conducted, and for child deaths a verbal autopsy was performed to ascertain the cause using a standardized diagnostic classification. Mortality due to pneumonia or diarrhea by age group and arm are shown in the outcome measure data table below.</description>
          <units>deaths per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17316"/>
                <count group_id="O2" value="17910"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Age group Mortality: 1- 5 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46"/>
                    <measurement group_id="O2" value="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age group Mortality: 6- 11 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47"/>
                    <measurement group_id="O2" value="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age group Mortality: 12 - 23 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29"/>
                    <measurement group_id="O2" value="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age group Mortality: 24 - 59 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15"/>
                    <measurement group_id="O2" value="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cause-specific Mortality Rate in Children Aged 1-60 Months, as Assessed From Verbal Autopsy (Malawi Only)</title>
        <description>Cause-specific mortality by intention-to-treat for the four main inferred causes of death in the study area.</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Biannual Mass Oral Azithromycin</title>
            <description>Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years.
In Niger during year 3, all communities will be offered azithroymcin.
Azithromycin: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.</description>
          </group>
          <group group_id="O2">
            <title>Biannual Mass Oral Placebo</title>
            <description>Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years
In Niger during year 3, all communities will be offered azithroymcin.
Placebo: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.</description>
          </group>
        </group_list>
        <measure>
          <title>Cause-specific Mortality Rate in Children Aged 1-60 Months, as Assessed From Verbal Autopsy (Malawi Only)</title>
          <description>Cause-specific mortality by intention-to-treat for the four main inferred causes of death in the study area.</description>
          <units>deaths per 1000 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39386"/>
                <count group_id="O2" value="39534"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" lower_limit="0.92" upper_limit="1.44"/>
                    <measurement group_id="O2" value="1.40" lower_limit="1.15" upper_limit="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68" lower_limit="3.25" upper_limit="4.17"/>
                    <measurement group_id="O2" value="3.84" lower_limit="3.40" upper_limit="4.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV/AIDS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" lower_limit="0.84" upper_limit="1.34"/>
                    <measurement group_id="O2" value="1.54" lower_limit="1.27" upper_limit="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" lower_limit="0.50" upper_limit="0.90"/>
                    <measurement group_id="O2" value="0.72" lower_limit="0.54" upper_limit="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 months.</time_frame>
      <desc>A SAE is any adverse event that:
Results in death
Is life-threatening (i.e., causes an immediate risk of death)
Requires inpatient hospitalization or prolongation of existing hospitalization
Results in persistent or significant disability or incapacity
Results in a congenital anomaly or birth defect
Or that is considered to be:
 An important medical event
SAE reporting excludes mortality as measured for the primary outcome.</desc>
      <group_list>
        <group group_id="E1">
          <title>Biannual Mass Oral Azithromycin</title>
          <description>Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years.
In Niger during year 3, all communities will be offered azithroymcin.
Azithromycin: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.</description>
        </group>
        <group group_id="E2">
          <title>Biannual Mass Oral Placebo</title>
          <description>Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years
In Niger during year 3, all communities will be offered azithroymcin.
Placebo: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3262" subjects_at_risk="97047"/>
                <counts group_id="E2" subjects_affected="3392" subjects_at_risk="93191"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3273" subjects_at_risk="97047"/>
                <counts group_id="E2" subjects_affected="3400" subjects_at_risk="93191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Suspected ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97047"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93191"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97047"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Suspected dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97047"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="93191"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97047"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93191"/>
              </event>
              <event>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="97047"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93191"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="3262" subjects_affected="3262" subjects_at_risk="97047"/>
                <counts group_id="E2" events="3392" subjects_affected="3392" subjects_at_risk="93191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="97047"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="93191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ARI</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97047"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="93191"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97047"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93191"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97047"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93191"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ying Lin</name_or_title>
      <organization>UCSF F.I. Proctor Foundation</organization>
      <phone>4155144709</phone>
      <email>ying.lin@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

